Mortality Reduction with Vena Cava Filters

Original Title: Outcomes after Vena Cava Filter Use in Non-Cancer Patients with Acute Venous Thromboembolism: A Population-Based Study. Reference: Richard H. White et al. Circulation. 2016 Apr 5. Epub ahead of print.
The evidence on the benefits of vena cava filters is limited. This retrospective study analyzed all patients with baseline oncological processes admitted to several centers for venous thromboembolism between 2005 and 2010.

The analysis was stratified according to the presence/absence of counterindication to anticoagulation (active bleeding/recent major surgery).

Primary end point was death at 30/90 days after admission and thromboembolism recurrence manifested as pulmonary embolism or deep vein thrombosis.

Propensity score was used to compare the populations given the systematic differences in baseline characteristics between patients receiving the filter and those who were not.

In 80697 patients with no anticoagulation counterindication, the use of vena cava filters (n=7762, 9.6%) did not significantly reduce mortality at 30 days (HR 1.12; IC 95% 0.98 a 1.28).

Among the 3017 patients with anticoagulation counterindication for active bleeding, the use of vena cava filters (N=1095, 36.3%) reduced mortality at 30 days in 32% (HR 0.68; CI 95% 0.52 a 0.88) and to 90 days a 27% (HR 0.73; 95% CI, 0.59-0.90).

The use of vena cava filters did not reduce mortality in 1445 patients receiving the filter in the context of venous thrombosis and after major surgery (HR 1.1; IC 95% 0.71 a 1.77).

The filter did not reduce thromboembolism subsequent risk of pulmonary embolism in any patient subgroup.

Deep ben thrombosis risk increased 50% in patients that could receive anticoagulation and 135% in those with active bleeding.

Conclusion
The implantation of vena cava filters significantly reduce mortality only in patients with vein thrombosis and anticoagulation counterindication for active bleeding.

More articles by this author

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...

STRIDE: Semaglutide in Patients with Peripheral Arterial Disease and Type II Diabetes

Peripheral arterial disease (PAD) is a severe complication in patients with type II diabetes, primarily affecting peripheral vessels, especially below-the-knee (BTK) arteries. This condition...

IVUS-Guided vs. Angiography-Guided Drug-Coated Balloon Angioplasty in the Treatment of Femoropopliteal Lesions

Angiography has traditionally been the primary imaging technique for endovascular therapy guidance in patients with peripheral artery disease. However, as it only provides two-dimensional...

New Carotid PCI All-in-One System

Carotid stenting is equivalent to carotid endarterectomy in terms of major adverse events (death, AMI, and stroke). However, it entails higher risk of minor...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...

STRIDE: Semaglutide in Patients with Peripheral Arterial Disease and Type II Diabetes

Peripheral arterial disease (PAD) is a severe complication in patients with type II diabetes, primarily affecting peripheral vessels, especially below-the-knee (BTK) arteries. This condition...